InsiderTrades.com logo
Enrique Poradosu net worth and biography
  • LinkedIn
  • Phone
  • Website

Enrique Poradosu Biography and Net Worth

Insider of Nuvectis Pharma

Dr. Enrique Poradosu co-founded and has served as the Chief Scientific and Business Officer of Nuvectis since 2020. From 2016 until 2020, he served as SVP, Business and Scientific Strategy at Stemline Therapeutics, Inc. (acquired by the Menarini Group in June 2020). At Stemline Enrique led the licensing and scientific strategy of the company’s pipeline, as well as directly leading strategic planning and operational execution of the early-stage drug development programs. Prior to that, Enrique served as VP Business and Scientific Strategy at Keryx Biopharmaceuticals, Inc. (acquired by Akebia Therapeutics), from 2003 until 2016. From 1998 until 2003, Enrique served as a project manager at a private biomedical incubator.

Enrique holds a BSc in Chemistry and Biology with distinction and a PhD in Biochemistry from the Hebrew University of Jerusalem, Israel.

What is Enrique Poradosu's net worth?

The estimated net worth of Enrique Poradosu is at least $15.24 million as of November 19th, 2024. Poradosu owns 1,506,319 shares of Nuvectis Pharma stock worth more than $15,236,417 as of May 7th. This net worth approximation does not reflect any other assets that Poradosu may own. Learn More about Enrique Poradosu's net worth.

How do I contact Enrique Poradosu?

The corporate mailing address for Poradosu and other Nuvectis Pharma executives is , , . Nuvectis Pharma can also be reached via phone at 201-614-3150. Learn More on Enrique Poradosu's contact information.

Has Enrique Poradosu been buying or selling shares of Nuvectis Pharma?

Enrique Poradosu has not been actively trading shares of Nuvectis Pharma over the course of the past ninety days. Most recently, on Tuesday, November 19th, Enrique Poradosu bought 2,000 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $4.99 per share, with a total value of $9,980.00. Following the completion of the transaction, the insider now directly owns 1,506,319 shares of the company's stock, valued at $7,516,531.81. Learn More on Enrique Poradosu's trading history.

Who are Nuvectis Pharma's active insiders?

Nuvectis Pharma's insider roster includes Enrique Poradosu (Insider), and Juan Sanchez (Director). Learn More on Nuvectis Pharma's active insiders.

Are insiders buying or selling shares of Nuvectis Pharma?

In the last year, Nuvectis Pharma insiders bought shares 11 times. They purchased a total of 246,632 shares worth more than $1,634,080.06. The most recent insider tranaction occured on November, 5th when CEO Ron Bentsur bought 5,000 shares worth more than $28,600.00. Insiders at Nuvectis Pharma own 30.5% of the company. Learn More about insider trades at Nuvectis Pharma.

Information on this page was last updated on 11/5/2025.

Enrique Poradosu Insider Trading History at Nuvectis Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2024Buy2,000$4.99$9,980.001,506,319View SEC Filing Icon  
5/10/2024Buy500$6.29$3,145.001,504,319View SEC Filing Icon  
3/27/2023Buy500$11.55$5,775.001,373,819View SEC Filing Icon  
See Full Table

Enrique Poradosu Buying and Selling Activity at Nuvectis Pharma

This chart shows Enrique Poradosu's buying and selling at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Company Overview

Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More

Today's Range

Now: $9.91
Low: $9.85
High: $10.49

50 Day Range

MA: $8.53
Low: $7.48
High: $10.00

2 Week Range

Now: $9.91
Low: $5.55
High: $11.15

Volume

61,389 shs

Average Volume

63,327 shs

Market Capitalization

$274.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A